NCT06784726 2026-03-13Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TUniversity of WashingtonPhase 2 Recruiting27 enrolled
NCT07042438 2026-03-05Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsCity of Hope Medical CenterPhase 2 Recruiting56 enrolled
NCT06834373 2026-01-28Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo ClinicPhase 2 Recruiting41 enrolled
NCT02570542 2025-11-26Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)Memorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting59 enrolled
NCT01110135 2017-05-24Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaUniversity of WashingtonPhase 2 Completed43 enrolled 5 charts